|
Sex (ref: Male)
|
0.0014
|
0.835 (0.747–0.933)
|
0.0013
|
0.825 (0.733–0.928)
|
|
Age (ref: < 75 years old)
|
0.0023
|
1.374 (1.120–1.686)
|
–
|
–
|
|
Histotype (ref: Other)
|
|
LMS
|
0.5114
|
0.955 (0.831–1.097)
|
–
|
–
|
|
DLPS
|
0.0068
|
1.357 (1.088–1.692)
|
–
|
–
|
|
MPNST
|
0.3703
|
1.154 (0.843–1.580)
|
–
|
–
|
|
SS
|
0.8580
|
0.983 (0.811–1.191)
|
–
|
–
|
|
UPS
|
0.0375
|
1.243 (1.013–1.525)
|
–
|
–
|
|
Grade (ref: < 3)
|
< 0.0001
|
1.417 (1.258–1.596)
|
< 0.0001
|
1.372 (1.218–1.546)
|
|
Number of metastatic sites (ref: 1)
|
0.1175
|
1.118 (0.972–1.285)
|
–
|
–
|
|
Liver metastasis (ref: no)
|
0.1436
|
1.103 (0.967–1.259)
|
–
|
–
|
|
Locoregional treatment (ref: no)
|
< 0.0001
|
0.496 (0.442–0.556)
|
< 0.0001
|
0.487 (0.432–0.550)
|
|
Clinical trial in first line (ref: no)
|
0.6453
|
1.048 (0.859–1.277)
|
–
|
–
|
|
Anthracycline in first line (ref: no)
|
< 0.0001
|
0.756 (0.674–0.847)
|
–
|
–
|
|
Polychemotherapy in first line (ref: no)
|
< 0.0001
|
0.729 (0.651–0.815)
|
< 0.0001
|
0.743 (0.660–0.836)
|
